NMN (Nicotinamide Mononucleotide) — Research Evidence
The summary below was generated by an AI system (Claude) based on the studies listed. It is a synthesis tool, not a clinical opinion. Read individual studies for full context.
NMN (Nicotinamide Mononucleotide) has accumulated a modest but growing body of human clinical evidence, primarily from short-term randomized controlled trials and supported by two meta-analyses. The overall picture suggests NMN can reliably raise blood NAD+ levels in humans, with some functional benefits emerging in specific populations — but the magnitude of real-world health benefits remains uncertain and the long-term data are essentially absent. Most claims about NMN's anti-aging potential still rest heavily on mechanistic rationale and animal studies rather than robust human outcome data.
Key findings
- ✓NMN supplementation consistently increases circulating NAD+ levels in human adults across multiple RCTs, confirming it is bioavailable and metabolically active.
- ✓A double-blind RCT in older adults found NMN maintained walking speed and improved sleep quality, suggesting modest functional benefits in aging populations.
- ✓An RCT in prediabetic women found NMN supplementation improved muscle insulin sensitivity, indicating a potentially relevant metabolic effect in at-risk groups.
- ✓A meta-analysis examining NMN and NR effects on skeletal muscle mass and function found some positive signals, though effect sizes and consistency across studies remain limited.
- ✓A meta-analysis on glucose and lipid metabolism found mixed results, suggesting metabolic benefits are not universal and may depend heavily on baseline health status and dose.
Evidence gaps
- ?There are no long-term (multi-year) human trials assessing whether NMN supplementation produces meaningful reductions in age-related disease, mortality, or sustained functional decline — all current RCTs are short-term.
- ?Optimal dosing, timing, and which populations are most likely to benefit remain poorly defined; most trials tested different doses and populations, making direct comparisons difficult.
- ?The translational gap between compelling animal aging data and human outcomes has not been bridged — it is unknown whether the NAD+ increases observed in human blood translate into the tissue-level and cellular benefits seen in preclinical models.
Safety summary
Short-term NMN supplementation in healthy adults appears to be well-tolerated with no serious adverse events reported across available RCTs, including a dedicated safety evaluation study. However, long-term safety data beyond several months are lacking, and caution is warranted before drawing conclusions about extended use.
Studies (20)
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials.
Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials.
Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach.
Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach.
NMN supplementation as a strategy to improve oocyte quality: a systematic review and transcriptomic analysis.
NMN supplementation as a strategy to improve oocyte quality: a systematic review and transcriptomic analysis.
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.
Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study.
Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study.
Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women.
Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women.
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial.
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial.
Regulation of and challenges in targeting NAD
Regulation of and challenges in targeting NAD
Research advances in the function and anti-aging effects of nicotinamide mononucleotide.
Research advances in the function and anti-aging effects of nicotinamide mononucleotide.
NAD
NAD
Mitochondrial Dysfunction and Therapeutic Perspectives in Cardiovascular Diseases.
Mitochondrial Dysfunction and Therapeutic Perspectives in Cardiovascular Diseases.
Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases.
Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases.
NAD
NAD
NAD
NAD
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update.
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update.
Nicotinamide mononucleotide (NMN) as an anti-aging health product - Promises and safety concerns.
Nicotinamide mononucleotide (NMN) as an anti-aging health product - Promises and safety concerns.
The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions.
The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions.